Current Use of sodium glucose co-transporter 2 inhibitors in heart failure therapy

Basit Öğe Kaydı
dc.authorscopusidTolga Sinan Güvenç / 6602421975
dc.authorwosidTolga Sinan Güvenç / JQN-5460-2023
dc.contributor.authorÇavuşoğlu, Yüksel
dc.contributor.authorAltay, Hakan
dc.contributor.authorÇelik, Ahmet
dc.contributor.authorGüvenç, Tolga Sinan
dc.contributor.authorKılıçarslan, Barış
dc.contributor.authorNalbantgil, Sanem
dc.contributor.authorTemizhan, Ahmet
dc.contributor.authorYıldırımtürk, Özlem
dc.contributor.authorYılmaz, Mehmet Birhan
dc.date.accessioned2025-04-18T07:10:07Z
dc.date.available2025-04-18T07:10:07Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractSodium-glucose cotransporter-2 inhibitors (SGLT2i) inhibit urinary glucose and sodium reabsorption in the proximal tubule of the nephron and result in glucosuria, natriuresis and diuresis. In patients with T2DM who have atherosclerotic cardiovascular (CV) disease or CV risk factors, SGLT2is is have been shown to reduce major CV events and heart failure (HF) hospitalization. The greatest and most consistent effect of SGLT2is in these trials was found to be reduction in HF hospitalization, which raised the possibility of clinical benefit of SGLT2i in HF patients. In DAPA-HF and EMPEROR-Reduced trials in heart failure with reduced ejection fraction (HFrEF) patients with or without T2DM, SGLT2İs, dapagliflozin and empagliflozin treatment on top of standard HF therapy has been shown to have clear clinical benefit in reducing primary endpoint of CV mortality or HF hospitalization and improving quality of life. Recently published EMPEROR-Preserved and DELIVER trials showed that SGLT2is were also very effective in the treatment of heart failure with preserved ejection fraction (HFpEF) (EF >40%). Furthermore, SGLT2is have also been shown to have potential in improving clinical outcomes in hospitalized acute HF patients in EMPULSE and DICTATE-AHF trials. All of this evidence has changed guidelines recommended therapies, not only for HFrEF but also for HFpEF treatment. The aim of this article is to provide a comprehensive overview focused on the role of SGLT2i in the treatment of HF based on the recent evidence.
dc.identifier.citationÇavuşoğlu, Y., Altay, H., Çelik, A., Güvenç, T. S., Kılıçarslan, B., Nalbantgil, S., ... & Yılmaz, M. B. (2024). Current Use of Sodium Glucose Co-transporter 2 Inhibitors in Heart Failure Therapy. Turk Kardiyoloji Dernegi arsivi: Turk Kardiyoloji Derneginin yayin organidir, 52(6), 429-454.
dc.identifier.doi10.5543/tkda.2024.52707
dc.identifier.endpage454
dc.identifier.issn10165169
dc.identifier.issue6
dc.identifier.scopus2-s2.0-85203117060
dc.identifier.scopusqualityQ3
dc.identifier.startpage429
dc.identifier.urihttp://dx.doi.org/10.5543/tkda.2024.52707
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6425
dc.identifier.volume52
dc.identifier.wosWOS:001355145600008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorGüvenç, Tolga Sinan
dc.institutionauthoridTolga Sinan Güvenç / 0000-0002-6738-266X
dc.language.isotr
dc.publisherTurkish society of cardiology
dc.relation.ispartofTürk kardiyoloji derneği arşivi
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDiabetes Mellitus
dc.subjectHeart Failure
dc.subjectSGLT2 Inhibitors
dc.titleCurrent Use of sodium glucose co-transporter 2 inhibitors in heart failure therapy
dc.typeOther

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Diğer Yayınlar Koleksiyonu